Teva falls on Celltrion warning letter, guidance

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) fell $2.21 (11%) to $18.64 in New York on Thursday after reporting earnings that included lower than expected 2018 guidance and indicated Teva may not be able to launch

Read the full 367 word article

User Sign In